平消片为主组合方案治疗乳腺增生症临床分析(1)
摘 要：目的 分析平消片為主组合方案治疗乳腺增生症的临床疗效。方法 选取我院2015年1月～2016年12月100例乳腺增生症患者作为观察对象，随机分为观察组和对照组，每组50例。对照组采用三苯氧胺联合平消片的治疗方案；观察组采用托瑞米芬联合平消片的治疗方案。比较两组患者的临床疗效以及不良反应发生率。结果 观察组与对照组的治疗有效率分别为92.00%和90.00%，两组相比，差异无统计学意义(P>0.05)。观察组不良反应发生率为6.00%，低于对照组的22.00%，差异具有统计学意义(P<0.05)。结论 三苯氧胺联合平消片与托瑞米芬联合平消片在乳腺增生症的临床治疗中均有较好的临床疗效，但托瑞米芬联合平消片的安全性更高，值得在临床中推广使用。
关键词：平消片；三苯氧胺；托瑞米芬；乳腺增生症
中图分类号：R271.44 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.08.046
, 百拇医药
文章编号：1006-1959(2018)08-0136-02
Clinical Analysis of the Combination of Pingxiao Tablets in the Treatment of Mammary Hyperplasia
YU Dong
(Department of Surgery，Wafangdian Traditional Chinese Medicine Hospital，Wafangdian 116300，Liaoning，China)
Abstract：Objective To analyze the clinical effect of Pingxiao tablet combined regimen in the treatment of mammary hyperplasia. Methods 100 patients with breast hyperplasia from January 2015 to December 2016 were randomly divided into observation group and control group with 50 cases in each group.The control group was treated with tamoxifen combined with Pingxiao tablet and the observation group with tolemiphene combined with pingxiao tablet.The clinical efficacy and incidence of adverse reactions were compared between the two groups.Results The effective rates of treatment were 92.00% and 90.00% in the observation group and the control group，respectively，there was no significant difference between the two groups(P>0.05).The incidence of adverse reactions in the observation group was 6.00%，which was lower than that in the control group 22.00%，and the difference was statistically significant(P <0.05).Conclusion The combination of tamoxifen and torreifene in the clinical treatment of hyperplasia of mammary glands has good clinical effect，but the safety of toromifene combined with Ping Xiao tablet is higher.It is worth popularizing in clinical practice.
, 百拇医药
Key words：Pingxiao tablet；Tamoxifen；Tolemiphene；Mammary hyperplasia
乳腺增生症(cyclomastopathy)是一种常见的妇科疾病，多发于25～50岁妇女中，该病在妇科疾病中的发生率为10%。该病在乳腺疾病中的比重超过70%，有一定的癌变倾向，尤其是不典型增生患者的癌变风险较高[1]。乳腺增生症的主要症状为乳房阵发性疼痛以及乳房肿块，对患者的工作与生活造成了较大的影响[2]。因此，需要通过积极的治疗来改善患者的生活质量。目前临床中主要是以平消片为主的联合治疗方案为主，并表现出了较好的应用效果。文章主要针对不同平消片组合方案在乳腺增生症的临床疗效展开分析，报道如下。
1资料与方法
1.1一般资料 选取2015年1月～2016年12月瓦房店中医医院收治的100例乳腺增生症患者作为观察对象，本次研究经医院伦理委员会批准。采用随机数字表法将患者分为观察组和对照组，每组50例。观察组年龄26～52岁，平均年龄(37.61±5.12)岁；病程3个月～5年，平均病程(1.21±0.50)年。对照组年龄22～51岁，平均年龄(35.60±5.31)岁；病程4个月～6年，平均病程(1.41±0.60)年。两组患者年龄、病程等一般资料方面相比，差异无统计学意义(P>0.05)，具有可比性。, 百拇医药(于东)
关键词：平消片；三苯氧胺；托瑞米芬；乳腺增生症
中图分类号：R271.44 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.08.046
, 百拇医药
文章编号：1006-1959(2018)08-0136-02
Clinical Analysis of the Combination of Pingxiao Tablets in the Treatment of Mammary Hyperplasia
YU Dong
(Department of Surgery，Wafangdian Traditional Chinese Medicine Hospital，Wafangdian 116300，Liaoning，China)
Abstract：Objective To analyze the clinical effect of Pingxiao tablet combined regimen in the treatment of mammary hyperplasia. Methods 100 patients with breast hyperplasia from January 2015 to December 2016 were randomly divided into observation group and control group with 50 cases in each group.The control group was treated with tamoxifen combined with Pingxiao tablet and the observation group with tolemiphene combined with pingxiao tablet.The clinical efficacy and incidence of adverse reactions were compared between the two groups.Results The effective rates of treatment were 92.00% and 90.00% in the observation group and the control group，respectively，there was no significant difference between the two groups(P>0.05).The incidence of adverse reactions in the observation group was 6.00%，which was lower than that in the control group 22.00%，and the difference was statistically significant(P <0.05).Conclusion The combination of tamoxifen and torreifene in the clinical treatment of hyperplasia of mammary glands has good clinical effect，but the safety of toromifene combined with Ping Xiao tablet is higher.It is worth popularizing in clinical practice.
, 百拇医药
Key words：Pingxiao tablet；Tamoxifen；Tolemiphene；Mammary hyperplasia
乳腺增生症(cyclomastopathy)是一种常见的妇科疾病，多发于25～50岁妇女中，该病在妇科疾病中的发生率为10%。该病在乳腺疾病中的比重超过70%，有一定的癌变倾向，尤其是不典型增生患者的癌变风险较高[1]。乳腺增生症的主要症状为乳房阵发性疼痛以及乳房肿块，对患者的工作与生活造成了较大的影响[2]。因此，需要通过积极的治疗来改善患者的生活质量。目前临床中主要是以平消片为主的联合治疗方案为主，并表现出了较好的应用效果。文章主要针对不同平消片组合方案在乳腺增生症的临床疗效展开分析，报道如下。
1资料与方法
1.1一般资料 选取2015年1月～2016年12月瓦房店中医医院收治的100例乳腺增生症患者作为观察对象，本次研究经医院伦理委员会批准。采用随机数字表法将患者分为观察组和对照组，每组50例。观察组年龄26～52岁，平均年龄(37.61±5.12)岁；病程3个月～5年，平均病程(1.21±0.50)年。对照组年龄22～51岁，平均年龄(35.60±5.31)岁；病程4个月～6年，平均病程(1.41±0.60)年。两组患者年龄、病程等一般资料方面相比，差异无统计学意义(P>0.05)，具有可比性。, 百拇医药(于东)